Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating front at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: The present invention relates an input controller (100) for interacting with a virtual environment, and more specifically to an input controller comprising a first body (102) and a second body (104) connected to the first body, wherein the first body comprises a first input device (106) and the second body comprises a second input device (108). The first input device provides input control to the virtual environment with a first movement with at least 5 degrees of freedom in the virtual environment, the first movement being a relative movement, and the second input device provides input control to the virtual environment with a second movement with at least 2 degrees of freedom in the virtual environment, the second movement being an absolute movement.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates an input controller (100) for interacting with a virtual environment, and more specifically to an input controller comprising a first body (102) and a second body (104) connected to the first body, wherein the first body comprises a first input device (106) and the second body comprises a second input device (108). The first input device provides input control to the virtual environment with a first movement with at least 5 degrees of freedom in the virtual environment, the first movement being a relative movement, and the second input device provides input control to the virtual environment with a second movement with at least 2 degrees of freedom in the virtual environment, the second movement being an absolute movement.

Abstract: An arrangement for locking arming conditions to prevent unintentional arming of SAI-units of ammunition units when the ammunition unit is subjected to external threats. A ring shaped shape memory alloy is provided in cooperation with a recess in a plunger arranged in connection to the SAI-unit and a fixed recess to prevent the plunger from axial movement when subjected to heating by changing the shape of the essentially ring shaped shape memory alloy to lock the plunger relative to the fixed recess.

Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating front at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneie donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: A packaging container comprises a first portion formed of a first material or material combination mainly consisting of plastic, a second portion formed of a second material or material combination mainly consisting of a fiber based packaging laminate, and a pouring opening formed in the first portion. The second portion is provided with an arrangement for separating the entire first portion from the second portion.

Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: An arrangement for locking arming conditions to prevent unintentional arming of SAI-units of ammunition units when the ammunition unit is subjected to external threats. A ring shaped shape memory alloy is provided in cooperation with a recess in a plunger arranged in connection to the SAI-unit and a fixed recess to prevent the plunger from axial movement when subjected to heating by changing the shape of the essentially ring shaped shape memory alloy to lock the plunger relative to the fixed recess.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes.

Abstract: This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation.

Abstract: The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; treatment using an agent capable of removing sialic acid on cell surfaces; and optionally culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising said vaccine and a pharmaceutically acceptable carrier and therapeutic use of said vaccine or said composition.

Abstract: The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed.